Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone

Long-Time Partners Decide Fate Of Two Drugs

 
• By Mandy Jackson
  
Illustration of abstract neuron on a blue background
Ionis will bolster its in-house neurology portfolio with wholly-owned ION582 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D